{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:52:46Z","timestamp":1794185566614,"version":"4.8.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ajo.2025.02.012","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T18:52:45Z","timestamp":1739472765000},"page":"119-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial"],"prefix":"10.1016","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2606-3734","authenticated-orcid":false,"given":"Usha","family":"Chakravarthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn H.","family":"Guymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra V.","family":"Rachitskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stela","family":"Vujosevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Vorwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Yasin","family":"Alibhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3859-3094","authenticated-orcid":false,"given":"Eric M.","family":"Moult","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco U.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline R.","family":"Baumal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia K.","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajo.2025.02.012_bib0001","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.ophtha.2013.11.023","article-title":"Geographic atrophy: clinical features and potential therapeutic approaches","volume":"121","author":"Holz","year":"2014","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.ajo.2025.02.012_bib0002","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"issue":"5-a Suppl","key":"10.1016\/j.ajo.2025.02.012_bib0003","first-page":"S2","article-title":"Geographic atrophy: mechanism of disease, pathophysiology, and role of the complement system","volume":"29","author":"Bakri","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.ajo.2025.02.012_bib0004","year":"2023","journal-title":"Drugs@FDA: FDA-Approved Drugs"},{"issue":"10411","key":"10.1016\/j.ajo.2025.02.012_bib0005","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ajo.2025.02.012_bib0006","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ophtha.2015.09.036","article-title":"Natural history of geographic atrophy progression secondary to age-related macular degeneration (Geographic Atrophy Progression Study)","volume":"123","author":"Schmitz-Valckenberg","year":"2016","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.012_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100351","article-title":"Macular sensitivity endpoints in geographic atrophy: exploratory analysis of Chroma and Spectri clinical trials","volume":"4","author":"Chang","year":"2023","journal-title":"Ophthalmol Sci"},{"issue":"17","key":"10.1016\/j.ajo.2025.02.012_bib0008","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41433-023-02497-w","article-title":"Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial","volume":"37","author":"Patel","year":"2023","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.ajo.2025.02.012_bib0009","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/biomedicines11061548","article-title":"Methodological appraisal of phase 3 clinical trials in geographic atrophy","volume":"11","author":"Biarn\u00e9s","year":"2023","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.ajo.2025.02.012_bib0010","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and Spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"10.1016\/j.ajo.2025.02.012_bib0011","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ophtha.2019.12.009","article-title":"Natural history of geographic atrophy secondary to age-related macular degeneration: results from the prospective Proxima A and B clinical trials","volume":"127","author":"Holekamp","year":"2020","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.ajo.2025.02.012_bib0012","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.oret.2020.01.019","article-title":"Visual function decline resulting from geographic atrophy: results from the Chroma and Spectri phase 3 trials","volume":"4","author":"Heier","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"9","key":"10.1016\/j.ajo.2025.02.012_bib0013","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1167\/iovs.17-22339","article-title":"Report from the NEI\/FDA endpoints workshop on age-related macular degeneration and inherited retinal diseases","volume":"58","author":"Csaky","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.ajo.2025.02.012_bib0014","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ICU.0000000000000153","article-title":"Introduction to microperimetry and its use in analysis of geographic atrophy in age-related macular degeneration","volume":"26","author":"Hanout","year":"2015","journal-title":"Curr Opin Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.012_bib0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/IAE.0000000000002337","article-title":"Mesopic and dark-adapted two-color fundus-controlled perimetry in geographic atrophy secondary to age-related macular degeneration","volume":"40","author":"Pfau","year":"2020","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.ajo.2025.02.012_bib0016","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.survophthal.2019.01.014","article-title":"Microperimetry for geographic atrophy secondary to age-related macular degeneration","volume":"64","author":"Csaky","year":"2019","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.02.012_bib0017","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000515148","article-title":"Clinical perspectives and trends: microperimetry as a trial endpoint in retinal disease","volume":"244","author":"Yang","year":"2021","journal-title":"Ophthalmologica"},{"issue":"2","key":"10.1016\/j.ajo.2025.02.012_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.xops.2023.100419","article-title":"Targeted high-density microperimetry testing of nascent geographic atrophy in age-related macular degeneration","volume":"4","author":"Wu","year":"2023","journal-title":"Ophthalmol Sci"},{"issue":"2","key":"10.1016\/j.ajo.2025.02.012_bib0019","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1167\/iovs.11-8415","article-title":"Macular function in macular degenerations: repeatability of microperimetry as a potential outcome measure for ABCA4-associated retinopathy trials","volume":"53","author":"Cideciyan","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ajo.2025.02.012_bib0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1167\/tvst.9.7.19","article-title":"Interpreting MAIA microperimetry using age- and retinal loci-specific reference thresholds","volume":"9","author":"Charng","year":"2020","journal-title":"Transl Vis Sci Technol"},{"issue":"11","key":"10.1016\/j.ajo.2025.02.012_bib0021","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1167\/iovs.63.11.4","article-title":"The fovea-protective impact of double-layer sign in eyes with foveal-sparing geographic atrophy and age-related macular degeneration","volume":"63","author":"Fukuyama","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.ajo.2025.02.012_bib0022","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.oret.2020.03.020","article-title":"Progression of unifocal versus multifocal geographic atrophy in age-related macular degeneration: a systematic review and meta-analysis","volume":"4","author":"Shen","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"10.1016\/j.ajo.2025.02.012_bib0023","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1167\/iovs.10-6075","article-title":"Changes in retinal sensitivity in geographic atrophy progression as measured by microperimetry","volume":"52","author":"Meleth","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2025.02.012_bib0024","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/IAE.0b013e3181e46af3","article-title":"Nidek MP1 is able to detect subtle decline in function in inherited and age-related atrophic macular disease with stable visual acuity","volume":"31","author":"Chen","year":"2011","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2025.02.012_bib0025","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1097\/IAE.0000000000000504","article-title":"MP1 and MAIA fundus perimetry in healthy subjects and patients affected by retinal dystrophies","volume":"35","author":"Parodi","year":"2015","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ajo.2025.02.012_bib0026","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1167\/iovs.09-4533","article-title":"Tracking progression with spectral-domain optical coherence tomography in geographic atrophy caused by age-related macular degeneration","volume":"51","author":"Fleckenstein","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"12","key":"10.1016\/j.ajo.2025.02.012_bib0027","doi-asserted-by":"crossref","first-page":"3992","DOI":"10.1167\/iovs.19-27178","article-title":"Light sensitivity within areas of geographic atrophy secondary to age-related macular degeneration","volume":"60","author":"Pfau","year":"2019","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.ajo.2025.02.012_bib0028","doi-asserted-by":"crossref","first-page":"6651","DOI":"10.1364\/BOE.433775","article-title":"Understanding the relationship between visual-angle and eye-angle for reliable determination of the field-of-view in ultra-wide field fundus photography","volume":"12","author":"Yao","year":"2021","journal-title":"Biomed Opt Express"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.012_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40942-024-00624-7","article-title":"Evaluating the reliability of a microperimetry-based method for assessing visual function in the junctional zone of geographic atrophy lesions","volume":"11","author":"Alibhai","year":"2025","journal-title":"Int J Retina Vitreous"},{"issue":"10","key":"10.1016\/j.ajo.2025.02.012_bib0030","doi-asserted-by":"crossref","first-page":"7640","DOI":"10.1167\/iovs.11-7457","article-title":"Semiautomated image processing method for identification and quantification of geographic atrophy in age-related macular degeneration","volume":"52","author":"Schmitz-Valckenberg","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2025.02.012_bib0031","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0896-1549(03)00013-0","article-title":"Visual acuity and its measurement","volume":"16","author":"Kniestedt","year":"2003","journal-title":"Ophthalmol Clin North Am"},{"issue":"10","key":"10.1016\/j.ajo.2025.02.012_bib0032","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0161-6420(97)30079-7","article-title":"Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity","volume":"104","author":"Sunness","year":"1997","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.02.012_bib0033","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1167\/iovs.65.1.36","article-title":"Visual sensitivity loss in geographic atrophy: structure-function evaluation using defect-mapping microperimetry","volume":"65","author":"Wu","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.ajo.2025.02.012_bib0034","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1167\/tvst.5.2.15","article-title":"The 24-2 visual field test misses central macular damage confirmed by the 10-2 visual field test and optical coherence tomography","volume":"5","author":"Grillo","year":"2016","journal-title":"Transl Vis Sci Technol"},{"issue":"6","key":"10.1016\/j.ajo.2025.02.012_bib0035","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1167\/iovs.62.6.7","article-title":"Focus on survival analysis for eye research","volume":"62","author":"McGuinness","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"}],"updated-by":[{"DOI":"10.1016\/j.ajo.2025.05.012","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000}}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425000686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425000686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:45:29Z","timestamp":1777567529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425000686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":35,"alternative-id":["S0002939425000686"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.02.012","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Visual Function Benefit After Treatment With Pegcetacoplan: Microperimetry Analysis From the Phase 3 Oaks Trial","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}